OTCMKTS: EVFM · Delayed Price · USD
0.0109
-0.0001 (-0.91%)
Jul 9, 2024, 9:44 AM EDT - Market open
| Market Cap | 676.46K |
| Revenue (ttm) | 16.01M |
| Net Income (ttm) | 50.52M |
| Shares Out | 62.06M |
| EPS (ttm) | -5.58 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 247,180 |
| Open | 0.0098 |
| Previous Close | 0.0110 |
| Day's Range | n/a |
| 52-Week Range | 0.0060 - 0.8200 |
| Beta | -0.74 |
| Analysts | Hold |
| Price Target | n/a |
| Earnings Date | Aug 29, 2023 |
About EVFM
Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vagin*l gel for the prevention of pregnancy. The company is also involved in the development of EVO100 for the prevention of chlamydia and gonorrhea in Women, and EVO200 for the prevention of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California. [Read more]
Industry Biotechnology
Sector Healthcare
CEO Ms. Saundra Pelletier
Employees 37
Stock Exchange OTCMKTS
Ticker Symbol EVFM
Full Company Profile
Financial Performance
Financial Statements
News
Hello Alpha Partners with Evofem to Offer Phexxi® as a Hormone-Free Contraception Solution on its Platform for Women's Healthcare
— Leading telemedicine company expands offering with hormone-free birth control as GLP-1 medication usage increases— — Hello Alpha partnership boosts awareness of and access to Phexxifor millions of...
Other symbols: ADTX
12 days ago - PRNewsWire
Evofem Announces Issuance of New U.S. Patent Covering Phexxi Composition of Matter
-- Issuance of U.S. Patent No. 11,992,472 Further StrengthensEvofem's Intellectual Patent Portfolio -- -- Newly issued patent is Evofem's fifth covering Hormone-Free "In the Moment" Contraceptive Phe...
Other symbols: ADTX
4 weeks ago - PRNewsWire
Evofem Biosciences Announces Financial Results for the First Quarter of 2024
SAN DIEGO , May 15, 2024 /PRNewswire/ -- The company behind the hormone-free contraceptive Phexxi®(lactic acid, citric acid and potassium bitartrate), Evofem Biosciences, Inc. ("Evofem" or "the Compa...
Other symbols: ADTX
7 weeks ago - PRNewsWire
Evofem Strengthens Phexxi Intellectual Property with New Composition of Matter Patent From USPTO
-- Application allowed with broad method claims that are Orange Book-listable -- -- Once issued, this will be Evofem's fifth patent covering Hormone-Free "In the Moment" Contraceptive Phexxiin the Un...
2 months ago - PRNewsWire
Evofem Reports $18.2 million of Phexxi Net Product Sales in 2023
-- Third Consecutive Year of Phexxi Net Sales Growth -- -- Total Operating Expense Reduced 64% from 2022 Levels -- -- Sales and marketing expense as a percentage of net sales was 54% for the fourth ...
Other symbols: ADTX
3 months ago - PRNewsWire
For Women Using GLP-1 Receptor Agonists who take Oral Birth Control Pills, Hormone-Free Phexxi Contraceptive Gel is a Logical Solution to Help Prevent Unintended Pregnancy
-- New weight loss drugs like Ozempic,Wegovyand Zepboundmay make oral birth control pills less effective at certain points -- SAN DIEGO , March 7, 2024 /PRNewswire/ -- Use of GLP-1 receptor agonists...
Other symbols: ADTX
4 months ago - PRNewsWire
Evofem Biosciences Announces Strong Preliminary Results, Record Phexxi Net Sales for Fiscal 2023
Evofem Delivers Third Consecutive Year of Phexxi Net Sales Growth Total Operating Expense Reduced More Than 60% from 2022 Levels SAN DIEGO , Feb. 1, 2024 /PRNewswire/ -- Evofem Biosciences, Inc. (OT...
Other symbols: ADTX
5 months ago - PRNewsWire
EVOFEM BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Evofem Biosciences, Inc. - EVFM
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Evofem Bioscienc...
Other symbols: ADTX
7 months ago - Business Wire
Shareholder Alert: Ademi LLP investigates whether Evofem Biosciences, Inc. has obtained a Fair Price in its transaction with Aditxt
MILWAUKEE , Dec. 12, 2023 /PRNewswire/ -- Ademi LLP is investigating Evofem (OTCQB: EVFM) for possible breaches of fiduciary duty and other violations of law in its transaction with Aditxt. Click here...
7 months ago - PRNewsWire
Evofem Biosciences Announces Financial Results for the Third Quarter of 2023
— On track to achieve third consecutive year of revenue growth – — Third consecutive quarter of favorable sales and marketing expense as a percentage of net sales — — Reduced loss from operations by 8...
8 months ago - PRNewsWire
Evofem to Participate in the Virtual Investor Ask the CEO Conference
-- Live moderated video webcast with members of Evofem management team on Tuesday, October 24th at 10:00 AM ET -- SAN DIEGO , Oct. 13, 2023 /PRNewswire/ -- Evofem Biosciences, Inc., (OTCQB: EVFM) (the...
9 months ago - PRNewsWire
Evofem Announces Padagis Will Not Seek FDA Approval to Market a Generic Version of Phexxi® Until Evofem's Phexxi Patents Expire
-- Padagis Determined They Will Not Challenge the Phexxi Patents -- -- Evofem Has Phexxi Patent Protection Through 2033 -- SAN DIEGO , Sept. 27, 2023 /PRNewswire/ -- Evofem Biosciences, Inc., (OTCQ...
10 months ago - PRNewsWire
Evofem Biosciences Successfully Amends S.P.A. with Institutional Investor
-- Investor withdraws March 2023 Notice of Default -- -- Notes are no longer convertible to shares of common stock, removing potential dilution from the previously-reserved over 240 million shares of...
10 months ago - PRNewsWire
Evofem Biosciences Signs Non-Binding Letter of Intent to Enable Listing on a National Stock Exchange
SAN DIEGO , Aug. 22, 2023 /PRNewswire/ --Evofem Biosciences, Inc. (OTCQB: EVFM) (Evofem or the Company) today announced it has signed a confidential non-binding letter of intent (LOI) relating to a p...
11 months ago - PRNewsWire
Evofem Biosciences Announces Financial Results for the Second Quarter of 2023
— On track to achieve third consecutive year of revenue growth – — Second consecutive quarter of favorable net product sales to sales and marketing expense ratio — — Reduced total operating expenses 6...
11 months ago - PRNewsWire
Evofem to Participate in the Virtual Investor Summer Spotlight Series
-- Live moderated video webcast with members of Evofem management team on Wednesday, July 12 th at 4:00 p.m. ET -- SAN DIEGO , July 6, 2023 /PRNewswire/ -- Evofem Biosciences, Inc., (OTCQB: EVFM) (the...
1 year ago - PRNewsWire
Evofem Biosciences Announces 1-for-125 Reverse Stock Split
--CUSIP number for Evofem will change to 30048L302 on May 18, 2023 -- -- Ticker symbol will change to "EVFMD" for 20 business days, then revert to "EVFM" -- SAN DIEGO , May 17, 2023 /PRNewswire/ -- E...
1 year ago - PRNewsWire
Evofem Biosciences Reports Year-End 2022 Financial Results and Provides Corporate Update
-- Net product sales more than doubled in 2022 vs. prior year -- -- Reduced total operating expenses by $74.1 million in 2022 vs.
1 year ago - PRNewsWire
Evofem Appoints Ivy Zhang as Chief Financial Officer and Secretary
SAN DIEGO , April 14, 2023 /PRNewswire/ -- Evofem Biosciences, Inc., (OTCQB: EVFM), the maker of Phexxi® (lactic acid, citric acid and potassium bitartrate), today announced the appointment ofIvy Zha...
1 year ago - PRNewsWire
Evofem Wins Phexxi Coverage with Largest Payer in New York with No Prior Authorization Required
SAN DIEGO, April 12, 2023 /PRNewswire/ -- Evofem Biosciences, Inc., (OTCQB: EVFM) today announced a major new win in New York state that improves coverage for Phexxi® (lactic acid, citric acid and pot...
1 year ago - PRNewsWire
Evofem Biosciences Announces Cost Reduction Measures
– Company cuts management pay and lowers headcount to decrease operating costs – – Reductions align with corporate goal to reach cash flow break even by year-end 2023 – SAN DIEGO , March 21, 2023 /PRN...
1 year ago - PRNewsWire
Evofem Biosciences Appoints Interim Chief Financial Officer
SAN DIEGO , March 9, 2023 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB: EVFM) is pleased to announce the appointment of Albert Altro as Interim Chief Financial Officer of the Company. He replaces J...
1 year ago - PRNewsWire
Evofem's Phexxi Contraceptive Gel Added to SimpleHealth Product Offering
-- Phexxi is the first and only hormone-free contraceptive offered by reproductive telehealth leader SimpleHealth to its patients -- SAN DIEGO , Feb. 28, 2023 /PRNewswire/ --Evofem Biosciences, Inc. ...
1 year ago - PRNewsWire
Evofem Biosciences Announces FDA Orange Book Listing of Two Additional U.S. Patents for Phexxi
-- Evofem now has four Orange Book listed patents covering Phexxi into 2033 -- SAN DIEGO , Feb.27, 2023 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB: EVFM) today announced thattwo additional U.S...
1 year ago - PRNewsWire
Evofem Biosciences to Explore Strategic Alternatives to Maximize Shareholder Value
SAN DIEGO , Feb. 23, 2023 /PRNewswire/ --Evofem Biosciences, Inc. (OTCQB: EVFM), announced today that its Board of Directors has unanimously approved a comprehensive strategic process to explore and ...
1 year ago - PRNewsWire
